Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)

Creative Medical Technology Holdings, Inc. is a biotechnology company focused on developing and commercializing novel biological therapeutics across various medical fields, including immunotherapy, endocrinology, urology, neurology, and orthopedics. The company operates through several subsidiaries, each targeting specific therapeutic areas and leveraging proprietary technologies to advance innovative treatments. Creative Medical Technology Holdings, Inc. was originally incorporated as Jolley Marketing, Inc. in 1998 and later rebranded following a reverse merger with Creative Medical Technologies, Inc. in 2016.

The company generates revenue through the development and commercialization of its therapeutic platforms and products. Key products and services include the ImmCelz platform, which utilizes reprogrammed immune cells for regenerative therapies, and the AlloStem platform, which offers allogenic cell lines for various indications. The company's customer base primarily consists of patients suffering from conditions such as Type 1 Diabetes, chronic lower back pain, and other immune-related disorders. Additionally, Creative Medical Technology Holdings, Inc. collaborates with research institutions and biotechnology firms to advance its therapeutic pipelines.

• ImmCelz Platform: This segment focuses on the development of the ImmCelz platform, which involves extracting a patient's own immune cells, reprogramming them outside the body, and reinjecting them to treat multiple indications. Key products include CELZ-100, which has shown promising results in reducing production costs and improving clinical outcomes for patients with immune disorders. The platform also includes the iPScelz program, developed in collaboration with Greenstone Biosciences Inc., which aims to create a viral-free cell line for therapeutic applications.

• AlloStem Platform: This segment centers on the AlloStem Clinical Cell Line, a proprietary allogenic cell line used for various therapeutic programs. Key products include CELZ-200, which supports the ImmCelz immunotherapy platform, OvaStem for Premature Ovarian Failure, and CELZ-201 CREATE-1 for Type 1 Diabetes. The AlloStemSpine procedure, targeting chronic lower back pain, is another significant development within this segment.

• StemSpine: This segment focuses on the StemSpine procedure, which has demonstrated efficacy in treating chronic lower back pain without serious adverse effects. The procedure involves the use of stem cells to promote regeneration and alleviate pain.

Creative Medical Technology Holdings, Inc. holds a unique position in the biotechnology industry, particularly in the field of regenerative medicine. The company's competitive advantages include its proprietary technologies, such as the ImmCelz and AlloStem platforms, which offer innovative solutions for complex medical conditions. Additionally, the company's strategic collaborations with research institutions and biotechnology firms enhance its ability to develop and commercialize cutting-edge therapies. The company's focus on personalized medicine and its ability to leverage artificial intelligence for drug discovery further strengthen its competitive position.

The company's customer base includes patients suffering from a range of conditions, including Type 1 Diabetes, chronic lower back pain, and other immune-related disorders. Creative Medical Technology Holdings, Inc. also collaborates with research institutions and biotechnology firms to advance its therapeutic pipelines. The company's commitment to innovation and its focus on addressing unmet medical needs position it as a key player in the biotechnology industry.